Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Food Effect Study of GB1211 Tablet vs Capsule in Healthy Volunteers
NCT05747573Phase 1Completed
- Sponsor
- Galecto, Inc.
- Start
- Jan 2023
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of selvigaltin in Liver cirrhosis (LC) and non-small cell lung cancer (NSCLC) (3 arms), sponsored by Galecto, Inc. Primary endpoints: Maximum Plasma Concentration at 5 weeks, Time to Reach Maximum Plasma Concentration at 5 weeks and 3 more. Started Jan 2023; status: completed.
02
Drugs
selvigaltin
03
Conditions
Liver cirrhosis (LC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05747573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05747573.